- The market for radiopharmaceuticals has the potential to grow to “tens of billions” if the drugs are proven to be effective.
- AstraZeneca’s bladder cancer drug durvalumab, called Imfinzi, reduced the risk of disease progression and recurrence by 32% and the risk of death by 25% in patients with bladder cancer in a global, clinical trial.
- Ponsegromab, a monoclonal antibody treatment from Pfizer, showed promising results in a clinical study aimed at treating the wasting condition cachexia in cancer patients. Patients treated with ponsegromab showed an increase in body weight after 12 weeks across various cancer types and drug dosages.
- AstraZeneca’s lung cancer drug datopotamab deruxtecan, called Dato-DXd, failed to show a significant benefit to overall survival when compared to docetaxel, a standard chemotherapy drug.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
